Results of Treatment with Pollen Extract (Cernilton ®N) in Prostatodynia and Chronic Prostatitis *
E. W. Rugendorff, W. Weidner , L. Ebeling, A. C. Buck
Summary (For the full study Click Here)
The results of a prospective case control study with the pollen extract Cernilton ®N** in the therapy of 90 patients with chronic prostatitis syndromes are reported. Cernilton ®N was given in a dose of one tablet three times daily for a period of six months. The following parameters were documented before and after three and six months of treatment: symptoms, findings on rectal palpation of the prostate, uroflow, leucocyturia in the midstream, and the first-voided 10-ml specimen after prostatic massage (VB 3), bacteriuria, and complement C3 / coeruloplasmin in the ejaculate.
* Submitted to Brit. J. Urol. 1992; with permission
Favorable results were obtained in the group of patients without associated complicating factors (N = 72): a response was observed in 56 (78 %) patients; 26 (36 %) were cured, and 30 (42 %) improved, with an increase in peak urine flow rate (ml / s) from 15.9 ± 5.2 to 23.5 ± 10.7 (x± s; p <0.001), a reduction of leucocyturia in VB 3 from 50 to 20 leucocytes /µl (median; p <0.001), and a decrease of complement C3 / coeruloplasmin (p <0.001) in the ejaculate. In cases with associated lower urinary tract pathology (N= 18), i.e., urethral strictures, prostatic calculi, bladder neck sclerosis, no response was observed with the exception of one patient who improved.
There was a strong qualitative (CCcorr = 0.720) and quantitative (r s= 0.565) inverse correlation between the changes in leucoyturia in VB 3 and peak urine flow rate.
Treatment was discontinued because of clinical deterioriation, mainly associated with symptomatic bacteriuria, or ineffective response in 13 (14,5 %) patients. The pollen extract was well tolerated in 96.7 % of cases. Three patients noted mild or moderate gastrointestinal symptoms, which did not lead to discontinuation of the therapy.
Regarding the common types of prostatitis syndromes, Cernilton ®N is considered to be most effective in prostatodynia and nonbacterial prostatitis in patients without complicating factors. The correlation between the therapeutic improvement of uroflow and inflammation suggests their functional relationship in the pathophysiology of the disease and a smooth muscle relexant (e.g., antiadrenergic) and / or anti-inflammatory mode of action of the pollen extract. Furthermore, if a patient fails to respond after three months of treatment with the pollen extract, a careful search for complicating factors is recommended.
** Pharma Stroschein (licensed by Cernitin SA, CH-6903 Lugano) D-2000 Hamburg 61